Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
5.43M
-
Number of holders
-
64
-
Total 13F shares, excl. options
-
8.93M
-
Shares change
-
-1.39M
-
Total reported value, excl. options
-
$45.4M
-
Value change
-
-$6.61M
-
Put/Call ratio
-
1.12
-
Number of buys
-
34
-
Number of sells
-
-28
-
Price
-
$5.10
Significant Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q1 2021
82 filings reported holding APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share as of Q1 2021.
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) has 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.93M shares
.
Largest 10 shareholders include Versant Venture Management, LLC (1.26M shares), MORGAN STANLEY (998K shares), BlackRock Inc. (811K shares), VANGUARD GROUP INC (753K shares), Redmile Group, LLC (695K shares), SG Americas Securities, LLC (656K shares), 5AM Venture Management, LLC (619K shares), Candriam Luxembourg S.C.A. (362K shares), TWO SIGMA ADVISERS, LP (339K shares), and TWO SIGMA INVESTMENTS, LP (323K shares).
This table shows the top 64 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.